CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Total revenues	$ 7,545	$ 7,051	$ 21,185	$ 20,002
Costs and expenses:
Cost of goods sold	1,574	1,565	4,670	4,408
Research and development expenses	1,395	1,457	4,266	4,310
Acquired in-process research and development expenses	505	91	4,674	808
In-process research and development impairment	1,750	0	4,180	0
Selling, general and administrative expenses	1,433	1,315	4,184	4,482
Total costs and expenses	6,657	4,428	21,975	14,009
Operating income (loss)	888	2,623	(790)	5,993
Interest expense	238	232	728	692
Other (income) expense, net	(306)	72	(41)	95
Income (loss) before income taxes	956	2,318	(1,477)	5,206
Income tax (benefit) expense	(297)	146	(174)	1,010
Net income (loss)	1,253	2,172	(1,303)	4,196
Net loss attributable to noncontrolling interest	0	(8)	0	(40)
Net income (loss) attributable to Gilead	$ 1,253	$ 2,180	$ (1,303)	$ 4,236
Basic earnings (loss) per share attributable to Gilead (in dollars per share)	$ 1.00	$ 1.75	$ (1.04)	$ 3.39
Shares used in basic earnings (loss) per share attributable to Gilead calculation (in shares)	1,247	1,248	1,247	1,249
Diluted earnings (loss) per share attributable to Gilead (in dollars per share)	$ 1.00	$ 1.73	$ (1.04)	$ 3.37
Shares used in diluted earnings (loss) per share attributable to Gilead calculation (in shares)	1,254	1,257	1,247	1,259
Product sales
Revenues:
Total revenues	$ 7,515	$ 6,994	$ 21,074	$ 19,864
Royalty, contract and other revenues
Revenues:
Total revenues	$ 30	$ 56	$ 111	$ 138